VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma.
作者： Anne Talvensaari-Mattila , Ylermi Soini , Markku Santala
DOI: 10.1159/000085589
关键词: Immunohistochemistry 、 Clinical significance 、 Angiogenesis 、 Vascular endothelial growth factor 、 Receptor expression 、 Cancer research 、 Immunostaining 、 Carcinoma 、 Medicine 、 Receptor
摘要: Vascular endothelial growth factor (VEGF) is associated with increased angiogenesis and aggressive tumour growth. We investigated the expression clinical significance of VEGF its receptors, flt-1 KDR/flk-1, in patients uterine endometrial carcinoma. The series consisted 115 endometrioid adenocarcinoma FIGO stage I–IV. Additionally, samples from 3 adenoacanthoma 12 poor prognostic variants carcinoma were examined. Immunohistochemical assessment was classified as negative or positive based on staining intensity. median follow-up time 87 months. In carcinomas, immunostaining rate 39% for VEGF, 65% 68% KDR/flk-1. There a significant correlation between both receptors. Furthermore, this receptor correlated two types VEGF-, flt-1- KDR/flk-1-positive immunostainings not related to prognosis. conclude that KDR/flk-1 expressions are useful markers overall survival
karger.com 
sci-hub.se 参考文章(25)
M. Detmar, A. M. Dvorak, L. F. Brown, H. F. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. ,vol. 146, pp. 1029- 1039 ,(1995)
V. Joukov, K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, K. Alitalo, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO Journal. ,vol. 15, pp. 290- 298 ,(1996) , 10.1002/J.1460-2075.1996.TB00359.X
Napoleone Ferrara, None, Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney International. ,vol. 56, pp. 794- 814 ,(1999) , 10.1046/J.1523-1755.1999.00610.X
Napoleone Ferrara, Terri Davis-Smyth, THE BIOLOGY OF VASCULAR ENDOTHELIAL GROWTH FACTOR Endocrine Reviews. ,vol. 18, pp. 4- 25 ,(1997) , 10.1210/EDRV.18.1.0287
Douglas Hanahan, Judah Folkman, Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis Cell. ,vol. 86, pp. 353- 364 ,(1996) , 10.1016/S0092-8674(00)80108-7
Petri Salven, Tarja Ruotsalainen, Karin Mattson, Heikki Joensuu, High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. International Journal of Cancer. ,vol. 79, pp. 144- 146 ,(1998) , 10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T
W Tjalma, E Van Marck, J Weyler, L Dirix, A Van Daele, G Goovaerts, G Albertyn, P van Dam, Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. British Journal of Cancer. ,vol. 78, pp. 170- 174 ,(1998) , 10.1038/BJC.1998.460
A. Kaipainen, J. Korhonen, T. Mustonen, V. W. van Hinsbergh, G. H. Fang, D. Dumont, M. Breitman, K. Alitalo, Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 3566- 3570 ,(1995) , 10.1073/PNAS.92.8.3566
M. G. Achen, M. Jeltsch, E. Kukk, T. Makinen, A. Vitali, A. F. Wilks, K. Alitalo, S. A. Stacker, Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proceedings of the National Academy of Sciences. ,vol. 95, pp. 548- 553 ,(1998) , 10.1073/PNAS.95.2.548
Eva Landgren, Petter Schiller, Yihai Cao, Lena Claesson-Welsh, Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 Oncogene. ,vol. 16, pp. 359- 367 ,(1998) , 10.1038/SJ.ONC.1201545